drugset / Trial / NCT02482441
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label Phase 1a/b dose-escalation study to assess the safety, tolerability, and PK of OMP-131R10 as a single agent for advanced solid tumors and in subjects with metastatic colorectal cancer.
Timeline
- Start
- 2015-07-16
- Primary completion
- 2018-01-26
- Completion
- 2018-03-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ROSMANTUZUMAB | Monoclonal antibody | 20 mg/kg | Intravenous |
| Background | Irinotecan | Small molecule | — | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |